Erratum to Severe Drug-Induced Skin and Liver Injury from Rivaroxaban (Dig Dis Sci, (2015), 10.1007/s10620-014-3504-9);Severe Drug-Induced Skin and Liver Injury from Rivaroxaban

Digestive Diseases and Sciences

Volumn 60, Issue 6, 2015, Pages 1856-1858

  Barrett, Patrick ^a   Vuppalanchi, Raj ^a   Masuoka, Howard ^a   Chalasani, Naga ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse drug reaction; DRESS; Drug induced skin reaction; Hepatotoxicity

Indexed keywords

CREATININE; LIVER ENZYME; METHYLPREDNISOLONE; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; AXILLA; CASE REPORT; COMORBIDITY; CREATININE BLOOD LEVEL; DRESS SYNDROME; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; EOSINOPHIL COUNT; FATIGUE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERTENSION; LEUKOCYTE COUNT; LEUKOCYTOSIS; LIVER BIOPSY; LIVER INJURY; LYMPHOCYTE COUNT; MACULOPAPULAR RASH; MALAISE; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROTEINURIA; SKIN BIOPSY; SKIN INJURY; TENOSYNOVITIS; TRUNK; BIOPSY; DRUG ERUPTIONS; DRUG-INDUCED LIVER INJURY;

AGED; BIOPSY; DRUG ERUPTIONS; DRUG-INDUCED LIVER INJURY; FACTOR XA INHIBITORS; HUMANS; MALE; MORPHOLINES; THIOPHENES;

EID: 84930384694     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3557-4     Document Type: Erratum

References (6)

1. FDA expands use of Xarelto to treat, reduce recurrence of blood clots. 2012. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm326654.htm. Accessed on 9/2/2014.
2. Chaudhari K, Hamad B, Syed BA. Antithrombotic drugs market. Nat Rev Drug Discov. 2014;13:571–572.
3. Boudes PF. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemp Clin Trials. 2006;27:432–440.
4. Russmann S, Niedrig DF, Budmiger M, et al. Rivaroxaban postmarketing risk of liver injury. J Hepatol. 2014;61:293–300.
5. Liakoni E, Ratz Bravo AE, Terracciano L, et al. Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. JAMA Intern Med. 2014;174:1683–1686.
6. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol. 2010;146:1373–1379.